Global PE funds in talks to buy 15% stake in Covid-19 drug maker BDR Pharma for Rs.1,200-Cr
Several global private equity funds, including the Carlyle Group, Warburg Pincus and TA Associates, are in talks to acquire a minority stake in Mumbai-based BDR Pharmaceuticals, a mid-size drug manufacturer. Promoters Dharmesh Shah and family plan to sell about 15% stake in the privately held company for INR 1,000-1,200 crore. In this first round of investment, BDR is likely to be valued at INR 7,000-7,500 crore. Investment bank O3 Capital is advising the promoters. BDR sells favipiravir under its brand name BDFAVI, besides manufacturing the drug for Sun Pharmaceuticals and Indoco Remedies.
Want to receive such news items in your inbox? Click Here to sign up for a trial.